Merus (MRUS)
(Delayed Data from NSDQ)
$49.67 USD
-1.14 (-2.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.67 USD
-1.14 (-2.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
by Zacks Equity Research
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Merus N.V. (MRUS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
by Zacks Equity Research
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Athenex Rallies on Positive Early Data on Psoriasis Candidate
by Zacks Equity Research
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
by Zacks Equity Research
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
by Zacks Equity Research
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1
by Zacks Equity Research
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
by Zacks Equity Research
Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
by Zacks Equity Research
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Will Merus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Merus.
Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
by Zacks Equity Research
Vertex (VRTX) gains a nod from Health Canada for Kalydeco to treat cystic fibrosis (CF) in children aged 12 to less than 24 months.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
by Zacks Equity Research
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara
by Zacks Equity Research
Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.
Merus Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merus has been struggling lately, but the selling pressure may be coming to an end soon.
Merus' Antibody Candidate in Phase II Breast Cancer Study
by Zacks Equity Research
Merus (MRUS) initiates a phase II study to evaluate its most advanced pipeline candidate in advanced breast cancer.